Apellis Pharmaceuticals to Host a Fireside Chat at the Jefferies London Healthcare Conference
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the Jefferies London Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) has announced its participation in the Jefferies London Healthcare Conference. The company will host a fireside chat on Tuesday, November 19, 2024, at 8:30 a.m. GMT. The event will be accessible through a live webcast on the company's website under the 'Events and Presentations' page in the 'Investors and Media' section. Interested parties can access a replay of the webcast, which will remain available for approximately 90 days after the event.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -1.08%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 8:30 a.m. GMT.
The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. We believe we have only begun to unlock the potential of targeting C3 across serious retinal, rare, and neurological diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.